31112-62-6 Usage
Description
Metrizamide, also known by the brand name Amipaque (GE Healthcare), is a non-ionic contrast agent related to Metrizoic Acid (M338935). It is a white, fine crystalline powder with a six-membered ring form, consisting of five carbon atoms and one oxygen atom, which is referred to as a pyranose sugar structure. In vivo, Metrizamide demonstrates minimal neurotoxicity, as it does not induce EEG abnormalities when administered at a dosage of 0.1 ml/kg of a 370 mg I/ml solution in rabbits.
Uses
Used in Medical Imaging:
Metrizamide is used as a diagnostic aid in the form of a radiopaque medium. It enhances the visibility of internal body structures during X-ray imaging procedures, allowing for better detection and diagnosis of various medical conditions.
Used in Gradient Centrifugation Applications:
Metrizamide has also been utilized as a solute in gradient centrifugation applications, which is a technique used to separate different types of cells or cellular components based on their size, shape, and density. This application takes advantage of Metrizamide's properties to create a stable and consistent gradient for effective cell separation.
Originator
Amipaque,Winthrop laboratories
Manufacturing Process
1 mole 3-(acetyl-methyl-amino)-2,4,6-triiodo-5-methylamino-benzoic acid was
suspended in thionyl chloride and reacted by stirring at 70°C for 16 hours.
Excess thionyl chloride was distilled off in vacuum, the residue dissolved in
chloroform, cooled in the ice bath, washed with iced water (3x100 ml),
saturated sodium bicarbonate solution (3 x 100 ml), 2 N sodium carbonate
solution (2 x 100 ml) and finally with water (3 x 100 ml). After drying with
CaCl2 the chloroform distilled off and residue dried in vacuum. Yield of 3-
acetylamino-5-(acetyl-methyl-amino)-2,4,6-triiodo-benzoyl chloride: 66%;
MP: 238°-240°C (the re-crystallization from tetrahydrofuran).It (0.02 mole) was dissolved in dioxan (120 ml). To the solution was added
(25 ml) and NaHCO3 (0.0022 mol). Glucosamine (0.022 mol) was added in
portions and reaction mixture left by stirring at room temperature for 24
hours. The solution was evaporated to dryness in vacuum, the residue
dissolved in water (500 ml), filtered clear and run through an Amberlite IR120 H+ ion exchange column. The effluent was evaporated to dryness in
vacuum resulting in a white crystalline residue. The crude 3-acetylamino-5-Nmethyl-acetylamino-2,4,6-triiodobenzoyl glucosamine was crystallised from
isopropanol (charcoal-treated when in solution), dissolved in water and
charcoal-treated at 100°C for 20 min. The water was distilled off in vacuum
and the white residue dried in vacuum at 70°C. MP: 190°-195°C.
Therapeutic Function
Diagnostic aid
Check Digit Verification of cas no
The CAS Registry Mumber 31112-62-6 includes 8 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 5 digits, 3,1,1,1 and 2 respectively; the second part has 2 digits, 6 and 2 respectively.
Calculate Digit Verification of CAS Registry Number 31112-62:
(7*3)+(6*1)+(5*1)+(4*1)+(3*2)+(2*6)+(1*2)=56
56 % 10 = 6
So 31112-62-6 is a valid CAS Registry Number.
InChI:InChI=1/C18H22I3N3O8/c1-5(26)22-12-9(19)8(10(20)14(11(12)21)24(3)6(2)27)17(30)23-13-16(29)15(28)7(4-25)32-18(13)31/h7,13,15-16,18,25,28-29,31H,4H2,1-3H3,(H,22,26)(H,23,30)/t7?,13?,15-,16+,18-/m1/s1
31112-62-6Relevant articles and documents
Amido derivatives of 2,4,6-triiodobenzoic acids containing at least one N-hydroxyalkyl and at least two hydroxyl groups
-
, (2008/06/13)
This invention relates to novel X-ray contrast agents particularly for use in the cerebrospinal cavities, comprising non-ionic alkanols carrying at least one N-bonded secondary or tertiary amide group and having at least two hydroxyl groups and at least one iodine atom in the molecule. Particularly useful compounds include the N-hydroxyalkyl iodoalkane sulphonamides having at least two hydroxyl groups, tri- and tetra-iodobenzene carrying carbamoyl, acylamino and/or acylaminomethyl substituents and having at least two hydroxyl groups in the molecule and at least one N-hydroxyalkyl group. Particularly preferred compounds comprise 2,4,6-triiodobenzamides which may be 3- and/or 5-substituted with a variety of groups. The compounds all show markedly low toxicities and a number show very high levels of water solubility.
